(S)he said what?!?

The type 2 diabetes population is big enough to be the world’s third largest country – how a new campaign is raising awareness by petitioning the UN to recognize type 2...

Twitter summary: BI/Lilly launch Jardiance in the US, making it the 3 rd SGLT-2 inhibitor on the market; savings program for one-year free supply After its recent FDA...

A how-to-guide for thriving in a toxic food environment that encourages bad choices.

German pharmaceutical company Merck KGaA has launched a pilot program in Kenya and Uganda to improve the outcomes of diabetes care through a text messaging campaign...

The countless things I am thankful for this year…Of course, I am most thankful for the health and happiness of my loving family, who I am lucky to say are my personal...

Twitter summary: Glooko launches MeterSync Blue, 30+ meters to send data to iPhone/Android app via Bluetooth using only 1 piece of hardware This month Glooko announced...

Expert Dr. Irl Hirsch’s eight tips for managing diabetes on a budget.

On July 3, Dr. Ed Damiano addressed the Friends for Life Conference in Orlando with the latest update on his team’s bionic pancreas, which involves automated insulin+...

Twitter Summary: Glucose info right on your wrist? Microsoft/Apple rumored smart watches might make that a reality We first wrote about Google’s venture into the...

Twitter summary: Contrave launched in the US w/ weight support program + savings/loyalty programs offer new option for patients Two healthcare companies, Orexigen and...

What are the most solvable problems in diabetes?

Twitter summary: BI/Lilly’s #insulin glargine receives EU approval – “Abrasia” set to launch in mid-2015 as 1 st ever “biosimilar” insulin in Europe On September 10, Eli...

How are the bacteria in our gut related to type 2 diabetes and obesity? The fascinating research.

On June 27, the FDA approved MannKind’s Afrezza for type 1 and type 2 diabetes, a new rapid-acting inhaled insulin. We’ve been following this story for years in diaTribe...

An illuminating FDA workshop on bolus calculators and device interoperability identifies key unmet needs in diabetes technology - Adam Brown makes a patient presentation!

On September 24, JAMA published a paper on long-term trends in the number of people with diabetes in the United States from 1980 to 2012. The results showed a leveling-...

What can diabetes advocates learn from the HIV/AIDS movement? Part five of our exclusive interview with David Panzirer and Dana Ball.

On June 19, Novo Nordisk announced the launch of its FlexTouch pen for the long-acting basal insulin Levemir (insulin detemir). FlexTouch, which has been approved in...

The curious milestone of a diabetes anniversary.